- £123.19m
- £117.00m
- £38.44m
Issue of Share Options / PDMR Shareholdings
Brief: Diaceutics Reports 22% Revenue Growth To £14.6 Mln In HY
22% Revenue Growth H125 representing 3-yr CAGR 25%
Expansion of PMx Commercialization Partnership
Notice of AGM and Posting of Annual Report
Transaction by Persons Closely Associated to PDMRs
Brief: Diaceutics Says Do Not Expect Direct Impact From Recent Tariff Announcements
FY 2024 Results - Strong Revenue Growth
PDMR Shareholding/Share Incentive Plan and TVR
Notice of Results
PDMR Shareholding/Share Incentive Plan and TVR
PMx Promotional Partner Contract Enhancement
Holding(s) in Company
PDMR Shareholding/Share Incentive Plan and TVR
Purchase of Shares and PDMR Shareholding
PDMR Shareholding/Share Incentive Plan
Brief: Diaceutics Sees FY ADJ EBITDA Ahead Of Analyst Consensus
FY 2024 Trading Update - Strong Revenue Growth
Brief: Diaceutics Announces Launch Of New PEL Service & Secures $1.8 Mln Contract